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Abstract The late gestational rise in glucocorticoids contributes to the structural and functional
maturation of the perinatal heart. Here, we hypothesized that glucocorticoid action contributes
to the metabolic switch in perinatal cardiomyocytes from carbohydrate to fatty acid oxidation.
In primary mouse fetal cardiomyocytes, dexamethasone treatment induced expression of genes
involved in fatty acid oxidation and increased mitochondrial oxidation of palmitate, dependent
upon a glucocorticoid receptor (GR). Dexamethasone did not, however, induce mitophagy or alter
the morphology of the mitochondrial network. In vivo, in neonatal mice, dexamethasone treatment
induced cardiac expression of fatty acid oxidation genes. However, dexamethasone treatment of pre-
gnant C57Bl/6 mice at embryonic day (E)13.5 or E16.5 failed to induce fatty acid oxidation genes
in fetal hearts assessed 24 h later. Instead, at E17.5, fatty acid oxidation genes were downregulated
by dexamethasone, as was GR itself. PGC-1α, required for glucocorticoid-induced maturation of
primary mouse fetal cardiomyocytes in vitro, was also downregulated in fetal hearts at E17.5,
24 h after dexamethasone administration. Similarly, following a course of antenatal corticosteroids
in a translational sheep model of preterm birth, both GR and PGC-1α were downregulated in
heart. These data suggest that endogenous glucocorticoids support the perinatal switch to fatty
acid oxidation in cardiomyocytes through changes in gene expression rather than gross changes in
mitochondrial volume or mitochondrial turnover. Moreover, our data suggest that treatment with
exogenous glucocorticoids may interfere with normal fetal heart maturation, possibly by down-
regulating GR. This has implications for clinical use of antenatal corticosteroids when preterm birth
is considered a possibility.
(Received 3 May 2021; accepted after revision 19 August 2021; first published online 10 September 2021)
Corresponding author Karen E. Chapman: University/BHF Centre for Cardiovascular Science, The Queen’s Medical
Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK. Email: Karen.Chapman@ed.ac.uk
Abstract figure legend Glucocorticoid treatment regulates fatty acid oxidation in cardiomyocytes. 24 hours after
glucocorticoid treatment, capacity for mitochondrial fatty acid oxidation is increased in fetal cardiomyocytes in vitro
(left) and in hearts of neonatal mice (right), with no alteration in expression of glucocorticoid receptor (GR). The
increase in fatty acid oxidation in fetal cardiomyocytes in vitro occurs without any change in mitochondrial number
or morphology (lower left). In contrast, fatty acid oxidation is down-regulated in fetal mice 24h after glucocorticoid
treatment (centre), likely because of down-regulation of GR. GR is also down-regulated in preterm lambs following
antenatal corticosteroid treatment in a sheepmodel of pretermbirth. These findings suggest that antenatal glucocorticoid
treatment may interfere with the normal trajectory of heart maturation by down-regulating GR.
Key points
 Glucocorticoids are steroid hormones that play a vital role in late pregnancy in maturing fetal
organs, including the heart.
 In fetal cardiomyocytes in culture, glucocorticoids promote mitochondrial fatty acid oxidation,
suggesting they facilitate the perinatal switch from carbohydrates to fatty acids as the predominant
energy substrate.
 Administration of a synthetic glucocorticoid in late pregnancy in mice downregulates the
glucocorticoid receptor and interferes with the normal increase in genes involved in fatty acid
metabolism in the heart.
 In a sheep model of preterm birth, antenatal corticosteroids (synthetic glucocorticoid) down-
regulates the glucocorticoid receptor and the gene encoding PGC-1α, amaster regulator of energy
metabolism.
 These experiments suggest that administration of antenatal corticosteroids in anticipation of pre-
term delivery may interfere with fetal heart maturation by downregulating the ability to respond
to glucocorticoids.
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
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Introduction
With birth and independent life comes the switch to
breathing air and exposure to a pro-oxidant environment
as well as a big increase in the workload of the heart and
a substantial increase in energy demand. The dramatic
increase in fetal glucocorticoid hormone concentration
in late gestation is essential to support this transition
from intrauterine to extrauterine life (Hillman et al.
2012; Rog-Zielinska et al. 2014). Administration of
potent synthetic corticosteroids (betamethasone or
dexamethasone) to pregnant women at risk of preterm
delivery is standard care in high- and middle-income
countries, with the aim of maturing the fetus to reduce
neonatal morbidity and mortality (Kemp et al. 2016;
Agnew et al. 2018). In addition to the well-known
effects on lung maturation (Cole et al. 1995; Bird et al.
2015; Laresgoiti et al. 2016), glucocorticoids promote
pro-survival adaptions in neonatal energy metabolism
and in the cardiovascular system (Hillman et al. 2012).
The heart undergoes profound changes at birth, with
a marked increase in cardiac output and transition
from a feto-placental blood circulation system to an
independent circulatory system. In the perinatal period,
cardiomyocyte proliferation ceases and cardiomyocytes
undergo terminal differentiation, involving extensive
binucleation and maturation of the myofibril structure,
calcium handling and inter-cellular communication.
Pre-clinical experiments, especially in sheep and rodent
models, have demonstrated the impact of glucocorticoids
and other hormones upon cardiac maturation (Hillman
et al. 2012; Rog-Zielinska et al. 2014). However, which of
the maturational effects of glucocorticoids on neonatal
energy metabolism and in the cardiovascular system
are directly attributable to glucocorticoid activation of
the glucocorticoid receptor (GR) within tissues and
which are mediated by other factors, such as thyroid
hormones (Forhead & Fowden, 2014) remains uncertain.
Indeed, there is a complex interdependence between
glucocorticoid and thyroid hormones in maturation
of organs and tissues in preparation for birth, with
glucocorticoids being important for maturation of the
thyroid axis (Hillman et al. 2012; Forhead & Fowden,
2014). Also unclear is whether antenatal administration
0 Jess Ivy completed her British Heart Foundation-funded MSc and PhD at the University of Edinburgh. She subsequently under-
took a postdoctoral position with Prof Karen Chapman aiming to understand the role of the glucocorticoid receptor in early
life programming of cardiovascular disease. She is currently a Kidney Research UK Intermediate Fellow at the University of
Edinburgh with a focus on the physiological consequences of abnormal glucocorticoid signalling on the renal molecular clock.
of potent synthetic glucocorticoids like dexamethasone
and betamethasone mimics endogenous glucocorticoid
action in the fetal cardiovascular system. Indeed,
exogenous glucocorticoid administration during late
gestation ‘programmes’ an increased risk of cardio-
vascular disease in adulthood (Fowden et al. 1998;
Rog-Zielinska et al. 2014). However, the direct effects
of exogenous glucocorticoid administration on cardio-
myocytes and other cells in the fetal heart (endothelial
cells, fibroblasts, immune cells, etc.) remain unclear
(reviewed, Rog-Zielinska et al. 2014; Agnew et al. 2018;
Song et al. 2019). Our previous data suggest antenatal
dexamethasone treatment dysregulates cardiac function
and downregulates endogenous glucocorticoid action in
the fetal heart (Agnew et al. 2019), potentially altering the
normal trajectory of perinatal cardiac maturation.
The normal increase in fetal glucocorticoids in late
gestation supports neonatal blood pressure (Hillman
et al. 2012) and is essential to structurally and
functionally mature the fetal heart (Thornburg et al.
2011; Rog-Zielinska et al. 2013). In utero, our ‘SMGRKO’
mice, with Sm22-Cre-mediated GR deficiency in cardio-
myocytes and vascular smoothmuscle cells show impaired
heart function, disrupted cardiac ultrastructure and
failure to induce key genes required for cardiac contra-
ctile function, calcium handling and energy metabolism
(Rog-Zielinska et al. 2013). Supporting direct effects of
GR, glucocorticoid treatment of primary mouse fetal
cardiomyocytes in vitro matures ultrastructure and
increases contractile function, mitochondrial capacity
(O2 consumption rate, basally and after uncoupling
of mitochondria) and markers of cardiomyocyte
maturation (Rog-Zielinska et al. 2015). Similarly, in
human embryonic stem cell (ESC)-derived cardio-
myocytes treated with dexamethasone, contractile force
is increased and systolic calcium transient decay is faster
(Kosmidis et al. 2015).
During the transition to a higher oxygen environment
and a greater cardiac workload at birth, the cardiac
preference for energy substrate switches. Substrates for
mitochondrial oxidative phosphorylation derive from
the tricarboxylic acid (TCA) cycle and other inter-
mediary pathways. Reducing equivalents, NADH and
FADH2, generated through the TCA cycle are the source
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
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of electrons which transfer through complexes I to
IV of the electron transport chain creating a proton
gradient across the inner mitochondrial membrane.
Electrons are ultimately transferred to O2 to produce
water or can be diverted to form superoxide and
reactive oxygen species (ROS). ATP synthase (complex
V) couples mitochondrial re-entry of protons to the
generation of ATP from ADP. The fetal heart generates
most of its ATP using acetyl CoA derived from glucose
and lactate oxidation, with only a minor contribution
from fatty acids. After birth, this switches so the
increased demand for ATP in the mature heart is
met primarily via oxidation of acetyl CoA generated
from mitochondrial fatty acid oxidation (Lopaschuk &
Jaswal, 2010). Carnitine palmitoyltransferase I (CPT-1)
transports long-chain fatty acids such as palmitate into
mitochondria where they are oxidized by a series of
enzymes including long-chain and medium-chain acyl
dehydrogenases (LCAD and MCAD, respectively) to
acetyl CoA which can then enter the TCA cycle. The
increase in fatty acid oxidation is associated with greater
mitochondrial functional capacity. PGC-1α, a master
transcriptional regulator of mitochondrial capacity, is
expressed in the late gestation fetal heart and expression
rises markedly after birth (Lehman et al. 2000). Mice with
global knockout of PGC-1α show 50% mortality before
weaning (Lin et al. 2004), suggesting that it is important
in the perinatal period. PGC-1α is a glucocorticoid
target gene and, in vivo in fetal heart, is induced 6 h
after glucocorticoid treatment in mice (Rog-Zielinska
et al. 2015). PGC-1α is also induced in vitro in primary
mouse fetal cardiomyocytes (Rog-Zielinska et al. 2015).
Here, the GR-mediated increase in PGC-1α expression
is crucial for the glucocorticoid-induced maturation
of myofibril structure and increased mitochondrial O2
consumption (Rog-Zielinska et al. 2015). Knock-down of
PGC-1α abolished both. RNAseq analysis performed on
primary mouse fetal cardiomyocytes harvested 2 h after
glucocorticoid addition in the presence of cycloheximide
(to block secondary effects) identified a number of
differentially expressed genes, likely to be primary targets
of GR (Rog-Zielinska et al. 2015). As well as Ppargc1a
(encoding PGC-1α), master regulators of mitochondrial
fatty acid oxidation (Klf15, Lipin1, Cebpb, Ppara) were
induced. This suggests that glucocorticoid action may
promote the perinatal switch in cardiomyocytes from
carbohydrate to fatty acid oxidation as the preferred sub-
strate for ATP generation.
Cellular differentiation is often associated with
metabolic remodelling and the autophagic turnover
of mitochondria by mitophagy (Rodger et al. 2018).
Mitophagic removal of small fetal mitochondria in peri-
natal cardiomyocytes is reportedly a prerequisite for the
formation of morphologically distinct adult mitochondria
and maturation into cardiomyocytes optimized for fatty
acid metabolism (Gong et al. 2015). The triggers for
mitophagy in perinatal cardiomyocytes are currently
unknown. mito-QC transgenic mice have a pH-sensitive
fluorescentmitochondrial signal thatmonitorsmitophagy
in vivo (McWilliams et al. 2016). Thesemice have revealed
that mitophagy is occurring at E17.5 in the mouse
fetal heart (McWilliams et al. 2016), a time coincident
with peak GR activation in heart (Rog-Zielinska et al.
2013). Furthermore, Bnip3, implicated in mitophagy, is
a direct GR target gene in primary fetal cardiomyocytes
(Rog-Zielinska et al. 2015), raising the possibility that
glucocorticoids may be a trigger for mitophagy in peri-
natal cardiomyocytes.
Here, we hypothesized that glucocorticoids increase
fetal cardiomyocyte capacity for fatty acid oxidation.
We also asked if any glucocorticoid-mediated increase
in mitochondrial fatty acid oxidation capacity involves
mitochondrial remodelling by mitophagy.
Materials and methods
Ethical approval
All experiments on mice were carried out in strict
accordance with accepted standards of humane animal
care under the auspices of the Animal (Scientific
Procedures) Act UK 1986. Experiments involving
mito-QC mice were carried out under the authority of
UK Home Office Project Licence PA3BFDB52 following
approval by the University of Dundee ethical review
committee with further study plan approval by the
Named Veterinary Surgeon and Compliance Officer.
Experiments involving all other mice were carried out
under the authority of UK Home Office Project Licence
P359AF310 following approval by the University of
Edinburgh AnimalWelfare and Ethical Review Body with
further approval of the experimental study plans by the
Named Veterinary Surgeon. Sheep experimentation and
protocols were approved by the animal ethics committee
of The University of Western Australia (RA/3/100/1452)
and maintained the standards of the Australian code for
the care and use of animals for scientific purposes, 8th
edition 2013.
Animals
Mice were maintained under controlled lighting and
temperature with ad libitum access to food and water.
C57BL/6J/Ola/Hsd (C57Bl/6J) mice were purchased from
Harlan, then bred in-house. GR+/– mice, heterozygous
for a null mutation in the Nr3c1 gene encoding GR
(Nr3c1gtESK92MRCHGU mice), have been previously
described (Michailidou et al. 2008; Rog-Zielinska
et al. 2013). GR+/– mice, congenic on the C57Bl/6J
background (>12 generations) were intercrossed to
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
J Physiol 0.0 Glucocorticoid regulation of fatty acid oxidation 5
give GR+/+, GR+/– and GR–/– fetal littermates. The
morning of the day the vaginal plug was found was
designated E0.5. Fetuses were collected at E17.5 and
killed by decapitation, hearts were dissected and
rapidly frozen on dry ice. Genotyping of fetal tissue
by PCR used LacZ primers for the Nr3c1gtESK92MRCHGU
(5’-GAGTTGCGTGACTACCTACGG-3’ and
5’-GTACCACAGCGGATGGTTCGG-3’) and wild-type
GR alleles as described (Michailidou et al. 2008).mito-QC
mice, also on a C57Bl/6J background, have been described
(McWilliams et al. 2016). mito-QC heterozygous fetuses
were used for fetal cardiomyocyte cultures. Fetuses were
collected and cardiomyocytes isolated as described below.
For dexamethasone treatment, pregnant C57Bl/6J
females (time-mated with C57Bl/6J males) were
semi-randomized to experimental group (n =
5/group/time point; alternating between groups as
lifted from the cage) and injected (∼0.1 ml, i.p.) with
dexamethasone (0.5 mg/kg; Sigma-Aldrich, Poole, UK) or
the vehicle used to dissolve dexamethasone (5% ethanol)
at either E13.5 or E16.5 and killed 24 h later (E14.5 and
E17.5, respectively) by cervical dislocation. Fetuses were
removed to ice-cold PBS and killed by decapitation.
Hearts were excised and frozen on dry ice. For analysis
of fetal heart RNA, one or two animals per litter were
analysed (where two animals from a litter were analysed,
the mean of the two was used), so n = 5. Neonatal
C57Bl/6J mice were injected (i.p.) on postnatal day 1 (P1;
day of birth being P0) with dexamethasone (0.5 mg/kg)
or vehicle (5% ethanol) and killed by decapitation (at P2)
24 h later (n = 7 vehicle-treated neonates from seven
different litters, n = 8 dexamethasone-treated neonates
from eight different litters). Hearts were removed and
frozen as above. Pregnant GR+/– dams were killed at
E17.5 by cervical dislocation. For RNA analysis, fetal
hearts were removed and frozen as above (n = 5–6
GR+/+ or GR–/– fetuses, from the litters of six dams)
for later RNA extraction. A different cohort of six pre-
gnant GR+/– dams were used for mitochondrial DNA
quantification with n = 6 GR+/+ and GR–/– fetuses,
each from a different litter; fetal hearts were removed
and frozen for later DNA extraction. All tissues were
identified by animal ID (blinding to genotype/treatment
group) and stored at -80°C prior to analysis. Merino ewes
were obtained from Icon Agriculture, Darkan, Western
Australia, Australia and had free access to food and water
throughout. Prior to delivery, animals were maintained
in an outdoor field environment with free access to
water and grazing. Supplemental feed (chaff, oaten hay,
sheep pellets) was provided twice daily. Date-mated
ewes carrying singleton pregnancies were randomized
to receive two injections (intramuscular) on days 120
and 121 of gestation, spaced by 24 h of either saline
(control; celestone is formulated in buffered saline) or
betamethasone acetate with betamethasone phosphate
(celestone chronodose, Merck & Co., Inc, Kenilworth,
NJ) 0.25 mg/kg per injection; n = 9/group (celestone), n
= 11/group (vehicle). A third group (n = 10) received a
single injection of betamethasone acetate (0.125 mg/kg).
Betamethasone acetate was a gift from Merck & Co. as
a preparation of betamethasone acetate equivalent to
that in celestone. Merck & Co. did not participate in the
design, execution or analysis of the study. The 0.25 mg/kg
celestone dose approximates the clinical dose of 12 mg of
betamethasone for a 50 kg woman and was the same dose
used for our previous studies (Kemp et al. 2018; Schmidt
et al. 2019a). To reduce the risk of steroid-induced pre-
term labour from antenatal corticosteroids, all pregnant
ewes, both steroid-treated and control animals, received
one intramuscular dose of 150 mg medroxyprogesterone
acetate (Depo-Provera, Pfizer, New York, NY) on day
115 of gestation, 5 days before corticosteroid treatment.
No other doses of medroxyprogesterone acetate were
administered, nor were other tocolytics administered. All
animals were delivered at 122 ± 1 days (term being ∼147
days).
Two days after their initial steroid or saline treatment,
on day 122 of gestation, ewes received an intravenous
injection of ketamine (10 mg/kg) and midazolam
(0.5 mg/kg). A spinal injection of 3 ml lignocaine
(20 mg/ml) was then administered and surgical delivery
commenced. Ewes were killed under anaesthesia at the
time of delivery. The lamb received an intramuscular
injection of ketamine (10 mg/kg) before placing a
4.5 mm endotracheal tube by tracheostomy. Lambs
were weighed, dried, and placed in an infant warmer
(Fisher & Paykel Healthcare, New Zealand). Inter-
mittent positive pressure ventilation was performed
using Acutronic Fabian infant ventilators (Acutronic
Medical System, Hirzel, Switzerland) and maintained
for 30 min using the following settings: initial peak
inspiratory pressure (PIP) of 40 cmH2O, positive end
expiratory pressure of 5 cmH2O, respiratory rate of
50 breaths per minute, inspiratory time of 0.5 s. Gas
mix was 100% heated and humidified oxygen. PIP was
titrated to achieve a tidal volume of 7 ml/kg. Lambs were
ventilated to assess preterm lung function in response to
antenatal steroid exposure as part of a separate study.
The ventilation procedure was brief (30 min) and
applied to both control (saline) and steroid-exposed
animals. Lambs were killed with an IV overdose of
pentobarbitone sodium at 160 mg/kg. Necropsy was
performed immediately following a 30 min ventilation
procedure which commenced at delivery. At necropsy
(within 40 min of delivery), left and right ventricles of the
heart were dissected and samples snap frozen.
Fetal cardiomyocyte cultures. Primary fetal cardio-
myocyte cultures were prepared as described
(Rog-Zielinska et al. 2015). Briefly, hearts were rapidly
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
6 J. R. Ivy and others J Physiol 0.0
dissected from 15–30 E14.5–E15.5 C57Bl/6J or mito-QC
fetuses. The number of fetuses differed between each cell
culture study, but pools always contained between 15 and
30 fetal hearts. E14.5 and E15.5 fetal hearts (after initiation
of fetal adrenal steroidogenesis) were combined to mini-
mize animal wastage; there is no discernible difference
between wild-type and GR-deficient mice at either time
point (Rog-Zielinska et al. 2013). Pooled hearts were
placed in warm Tyrode’s salt solution containing 0.1%
sodium bicarbonate then rinsed in complete medium
(DMEM supplemented with 100 IU/ml penicillin,
100 mg/ml streptomycin, 10% fetal bovine serum, 0.1%
non-essential amino acids, Sigma-Aldrich, Poole, UK)
before digestion at 37°C with gentle agitation for 10 min
in 5 ml enzyme buffer (PBS supplemented with 0.8%
NaCl, 0.2% D-(+)-glucose, 0.02% KCl, 0.000575%
NaH2PO4·H2O, 0.1% NaHCO3, pH 7.4) containing
0.03% type II collagenase (Worthington Biochemical
Corp, Lakewood, New Jersey, USA), 0.125% porcine
pancreatin (Sigma-Aldrich, Poole, UK). After 10 min,
isolated cells and enzyme buffer were removed and
the enzymatic reaction quenched by adding the same
volume of complete medium. Fresh enzyme buffer was
then added to the hearts. Approximately eight digestions
were performed on the hearts until their structure
was lost. Isolated cells were centrifuged at 1000 g for
10 min at room temperature, the supernatant removed
and pellets pooled. Pooled cells were centrifuged again
and resuspended in 15 ml isolation buffer (Ham’s F12
supplemented with 100 IU/ml penicillin, 100 mg/ml
streptomycin, 0.002% ascorbic acid, 1% fetal bovine
serum, 0.1176% NaHCO3). To reduce the number of
fibroblasts, cells were incubated in a tissue culture plate
(ThermoFisher, UK) at 37°C, 5% CO2 for 3 h during
which fibroblasts adhered to the plastic. Non-adherent
cells were aspirated, centrifuged, resuspended in 1 ml
of complete medium and seeded at a density of 0.25
× 106 cells/ml for extracellular flux (ECF; seahorse)
assays, RNA analysis or mitochondrial morphology.
This protocol yields ≥98% cardiomyocytes (troponin T+
cells) (Rog-Zielinska et al. 2015). Spontaneous beating of
cardiomyocytes was observedwithin 12 h. For ECF assays,
cardiomyocytes were seeded onto 24-well gelatin (Sigma,
UK) coated V7 seahorse plates (Agilent Technologies
LDA UK Ltd, Stockport, Cheshire, UK) in complete
medium then treated with dexamethasone (1 μM) or
vehicle (0.01% ethanol) for 24 h prior to ECF assay
(below). We have previously shown that this dose of
dexamethasone elicits maximal glucocorticoid responses
in fetal cardiomyocytes (Rog-Zielinska et al. 2015). For
RNA analysis, primary fetal cardiomyocytes were seeded
in 12-well gelatin-coated tissue culture plates for 48 h.
Cells were treated with dexamethasone (1 μM) or vehicle
(0.01% ethanol) and lysed 6 or 24 h later by adding
0.5 ml TRIzol (Invitrogen, ThermoFisher, UK) following
removal of medium. For measurement of mitochondrial
morphology and mitophagy, cardiomyocytes were
cultured on gelatin-coated glass chambered slides (Ibidi
μ-slide 4-well glass bottom, Thistle Scientific LTD,
Glasgow, UK) prior to staining.
Extracellular flux assays. ECF assays were carried
out using a Seahorse XFe24 Bioanalyzer (Agilent
Technologies LDA UK Ltd, Stockport, Cheshire, UK).
All seahorse reagents were purchased from Agilent
Technologies LDA UK Ltd. The oxygen consumption
rate (OCR) and extracellular acidification rate (ECAR)
were measured. The basal OCR reflects mitochondrial
oxidative phosphorylation, non-mitochondrial cellular
metabolism (e.g. dioxygenases), ROS production and
proton leak (basal mitochondrial respiration not coupled
to ATP production). The ECAR reflects lactate released
as a product of glycolysis and also acidification by
mitochondrial production of CO2. Inhibitors were
used to assess the contributions of glycolysis and
mitochondrial complexes to ECARandOCR, respectively.
2-deoxyglucose (2DG) is phosphorylated by hexokinase,
the first and rate-limiting enzyme in glycolysis, but
cannot be further metabolized, so inhibits glycolysis.
Oligomycin blocks the proton channel of ATP synthase
(complex V), thus preventing oxidative phosphorylation
of ADP to ATP, providing a measure of mitochondrial
ATP generation. Rotenone and antimycin A inhibit
complex I and complex III of the mitochondrial electron
transport chain, respectively, completely blocking
mitochondrial electron transport and thus mitochondrial
respiration. Any residual oxygen consumption following
addition of antimycin A and rotenone (AR) is
independent of mitochondrial respiration. Carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP)
allows protons through the mitochondrial membrane,
uncoupling mitochondrial electron transport from
proton transfer and ATP generation. FCCP thus permits
electron transport and oxygen consumption by complex
IV to proceed maximally, providing a measure of
mitochondrial reserve capacity. For each experiment,
treatment groups were randomized across the plate. Each
well was assigned a number (based on the number of
treatment groups) so that numbers were spread across the
plate. Treatments were then randomized to numbers. On
the day of the assay, complete culture medium was gently
aspirated from the cells and exchanged for seahorse assay
medium (with supplements defined below). The cells were
gently rinsed three times with seahorse assay medium,
leaving a final volume of 525 μl for the assay. During
all assays, three measurements at 2.5 min intervals,
were recorded at baseline and after each drug addition.
Each figure shows data from a different experiment or
experiments.
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
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Normalization of extracellular flux assays using
sulforhodamine B assay. ECF assays were normalized
to protein measured using sulforhodamine B (SRB)
dye-based protein assay (Skehan et al. 1990). Initial
experiments confirmed the linearity of the SRB assay for
use in quantifying primary cardiomyocyte protein levels
(R2 = 0.93; Fig. 1A, n = 3). Following ECF assays, cells
were fixed by addition of 50 μl cold 50% trichloroacetic
acid (Sigma-Aldrich, Poole, UK) per well and stored for
up to 1 week at 4°C. Cells were then washed 10 times with
tap water and air-dried. Fifty microlitres of SRB solution
(0.4% w/v sulforhodamine B dye (Sigma-Aldrich, Poole,
UK) in 1% acetic acid (Sigma-Aldrich, Poole, UK)) was
added to dried cells and incubated for 30 min at room
temperature. Cells were washed four times with 1% acetic
acid and air-dried. Cell-bound dye was redissolved in
200μl 10mMTris pH10.5. Absorbancewasmeasured at a
wavelength of 540 nm. There was no difference in protein
content, measured by SRB assay, between dexamethasone
and vehicle-treated cells (2.82 ± 0.0373 vehicle vs. 2.83 ±
0.0374 dexamethasone, n = 10 wells/treatment from one
experiment, P = 0.803 by t test).
Glycolysis assays. Assays to estimate the rate of glycolysis
in fetal cardiomyocytes were performed in two different
ways. In the first, a glycolysis stress test was performed
according to the manufacturer’s protocol. Briefly, the cells
were incubated in pre-warmed glucose-free seahorse-XF
base medium for 1 h in a (non-CO2) 37°C incubator
prior to the assay. After three basalmeasurements, glucose
(Sigma-Aldrich, Poole, UK, 10 mM) was added to enable
glycolysis, followed by oligomycin (Sigma-Aldrich, Poole,
UK, 1.5 μM) to inhibit respiratory ATP production and
finally 2DG (Sigma-Aldrich, Poole, UK, 100 mM) to
inhibit glycolysis. In the second, complete culturemedium
was exchanged for pre-warmed seahorse assay medium
supplemented with 10 mM glucose (Sigma-Aldrich,
Poole, UK), 1 mM sodium pyruvate (Sigma-Aldrich,
Poole, UK). After basal OCR/ECAR measurements, 2DG
(Sigma-Aldrich, Poole, UK, 100mM)was added to inhibit
glycolysis, followed by AR (Sigma-Aldrich, Poole, UK,
2 μM) to inhibit the electron transport chain.
Fatty acid oxidation assay. To test the ability of primary
fetal cardiomyocytes to utilize long-chain fatty acids,
cells were pre-treated with etomoxir (Sigma-Aldrich,
Poole, UK) to inhibit the CPT-1 mitochondrial fatty
acid uptake transporter, prior to performing a standard
seahorse mitochondrial stress test (Fig. 1B). Initial
experiments with high concentrations of etomoxir
(40–160 μM) reduced OCR in the presence of bovine
serum albumin (BSA)-palmitate (Fig. 1C). However,
within this range (120 μM), etomoxir also showed
likely off-target inhibition of mitochondrial respiration
(Fig. 1B). This is consistent with an emerging literature
showing that etomoxir can inhibit complex I at commonly
used high doses (Divakaruni et al. 2016; Yao et al.
2018). Accordingly, we used 6 μM etomoxir for
all further experiments, a dose which inhibits fatty
acid oxidation and avoids the CPT-1-independent
effects associated with higher doses (Spurway et al.
1997). Briefly, culture medium was exchanged for
seahorse assay medium supplemented with 5 mM
glucose (Sigma-Aldrich, Poole, UK), 0.5 mM carnitine
(Sigma-Aldrich, Poole, UK). Cells were pre-treated
with etomoxir (6 μM in medium) or vehicle (medium)
15 min prior to the addition of BSA-palmitate (100 μM;
Agilent Technologies LDA UK Ltd). The seahorse
mitochondrial stress test assay was started 15 min
after the addition of BSA-palmitate. Briefly, the test
progressed as follows: basal respiration measurements,
addition of oligomycin (1.5 μM), addition of carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP;
1 μM), addition of AR (2 μM). Non-mitochondrial
respiration was calculated as the minimum OCR
remaining following AR treatment. The mean of the
three baseline measurements was used for the basal
OCR. Basal respiration was calculated by subtracting
non-mitochondrial respiration from basal OCR. ATP
production was calculated as the maximum change
in OCR following the addition of oligomycin and
maximum respiration was calculated as the maximum
OCR measurement induced by FCCP corrected for
non-mitochondrial respiration. Leak respiration was
calculated as the average oligomycin-insensitive OCR
corrected for non-mitochondrial respiration.
Measurements of mitochondrial morphology. On the
day of staining of primary fetal cardiomyocytes, complete
culture medium was exchanged for serum-free medium.
MitoTracker Deep Red (40 nM; ThermoFisher, UK)
was added and incubated for 30 min in cell culture
conditions. Serum-free medium was then replaced. To
image cardiomyocytes as a z stack, beating was stopped
by adding 100mMnefidipine (Sigma-Aldrich, Poole, UK)
immediately prior to imaging using an Andor Spinning
Disk confocal microscope. The Andor Spinning Disk
system is based on an inverted Olympus IX83 micro-
scope stand and a Yokogawa CSU-X1 spinning disk
module. It is equipped with an Oko Labs environmental
control chamber to maintain stable conditions for live cell
imaging; 37°C, 5% CO2 were used throughout. To acquire
GFP and mCherry images, 488 nm (BP525/25) and
561 nm (LP568), respectively, laser lines (and emission
filters) operated via an AOTF were used. A plan super
apochromat 100 × 1.4 NA oil immersion objective was
used throughout, with z steps of 1 μm taken. Images
were acquired onto an Andor iXon Ultra EMCCD
camera (512 × 512) using an EM gain of 200 with
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
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Figure 1. Optimization experiments for extracellular flux assays in primary fetal cardiomyocytes
All experiments were performed using primary fetal cardiomyocytes prepared by digesting 15–30 pooled C57BL6/J
fetal hearts at E14.5–15.5 and cultured for 48 h in complete DMEM culture medium. A, the sulpho-rhodamine
assays, used to estimate protein levels for normalization of extracellular flux assays, was linear over a range of
primary fetal cardiomyocyte seeding densities, n = 3 wells of pooled cells, line fitted by linear regression with
R-square value of 0.93. B, cell culture complete mediumwas exchanged for seahorse assay medium (supplemented
with 1 mM GlutaMAX, 10 mM glucose, 1 mM pyruvate and 0.5 mM carnitine). Cardiomyocytes were treated with
BSA-palmitate (100 μM) 30 min prior to extracellular flux analysis. After three basal measurements, Etomoxir (Eto)
was added (120 μM), followed by oligomycin (1.5 μM), carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
(FCCP, 1 μM) and antimycin and rotenone (AR, 2 mM). After Eto-treatment, these cells failed to uncouple in
response to FCCP and exhibited a very small response to AR consistent with the emerging literature that Eto can
inhibit complex I and III at high concentrations. C, cardiomyocytes were treated with BSA-palmitate (100 μM) in
seahorse assay medium 30 min prior to extracellular flux analysis. The change in oxygen consumption rate (OCR)
with increasing doses of Eto was measured (indicated in panel (B) by a dotted line). Dose response experiments
with increasing doses of Eto indicated that doses of 40–120 μM gave similar % changes in OCR, n = 3–5 wells
of pooled cells. D–G, finally, the effect of Eto in the absence of the fatty acid palmitate was investigated. Cell
culture complete medium was exchanged for seahorse assay medium (supplemented with 1 mM GlutaMAX,
5 mM glucose and 0.5 mM carnitine). Cells were treated with Eto (6 μM) or vehicle (Control, medium) 15 min
prior to the addition of BSA alone (17 μM). After 15 min incubation, cardiomyocyte metabolism was analysed by
extracellular flux assays. After three basal measurements, oligomycin was added (1.5 μM) followed by carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 1 μM) and AR (2 mM). OCR (A) was measured in triplicate for
2.5 min following each drug addition. Non-mitochondrial respiration was estimated as the average OCR remaining
after treatment with AR. D, basal respiration was estimated as the mean of the three basal OCR measurements
corrected for non-mitochondrial respiration. E, ATP production was estimated as the maximum change in OCR
following the addition of oligomycin. F, maximum respiration was estimated by the maximum OCR measurement
induced by FCCP corrected for non-mitochondrial respiration. G, leak respiration was estimated as the average
oligomycin-insensitive OCR corrected for non-mitochondrial respiration. Data are means ± SD, data analysed by
Student’s t tests, n = 5 individual wells of primary fetal cardiomyocytes pooled from 15–30 fetal hearts analysed
at the same time across one experiment.
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
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50 ms exposure. Mitochondrial volume was quantified
using open-source MitoGraph software (Viana et al.
2015; Harwig et al. 2018). This uses 3D reconstructions
of labelled organelles to measure the morphology of
individual mitochondria as well as characteristics of
the mitochondrial network and provides the following
outputs: mitochondrial volume, total length and average
width. Post-image processing and MitoGraph analysis
was performed as per the online protocols (available:
http://rafelski.com/susanne/MitoGraph). Between 17 and
40 individual cardiomyocytes from one experiment were
quantified in the data shown here (a replicate experiment
with the same findings is not reported).
Mitophagy assay. Primary fetal cardiomyocyte cultures
prepared from E14.5–15.5 mito-QC fetuses were seeded
at a density of 0.25 × 106 cells/ml on gelatin-coated
glass chambered slides (Ibidi μ-slide 4-well glass
bottom, Thistle Scientific LTD, Glasgow, UK). After
48 h, cells were treated with 1 μM dexamethasone,
1 mM deferiprone (DFP, an iron-chelator, used as a
positive control) or vehicle (0.01% ethanol). After 24 h
dexamethasone/DFP/vehicle-treated cells were imaged
live and z stacks were generated 3, 8 and 45 h after
treatment, using the Andor Spinning Disk confocal live
cell imaging system as above. Post-acquisition image
analysis was performed blind to the treatment. For each
cell, a z stack was acquired and red puncta, indicative of
mitophagy, were counted.
RNA extraction. Primary fetal cardiomyocytes seeded in
12-well plates were lysed in 500 μl TRIzol (Invitrogen,
ThermoFisher, UK) and aspirated into a 1.5 ml tube.
Chloroform (Sigma-Aldrich, Poole, UK; 100 μl) was
added and samples vigorously shaken for 30 s. Samples
were incubated for 2–3 min at room temperature then
centrifuged 10,000 g for 15 min at 4°C. The aqueous
phase was transferred to a new tube containing 250 μl
isopropanol (Sigma-Aldrich, Poole, UK) and centrifuged
as above. The supernatant was discarded and the pellet
washed with 500 μl 70% ethanol twice. Samples were
centrifuged at 10,000 g for 10 min at 4°C, the supernatant
removed and pellet air-dried at room temperature for
5–10 min before resuspension in 30 μl RNAse-free water.
Mouse fetal hearts were individually homogenized
using a stainless steel bead in 500 μl RLT buffer (RNeasy,
Qiagen, Manchester, UK) and 1% β-mercaptoethanol
with a TissueLyser II (Qiagen, Manchester, UK) at
maximum speed for 2 min. Ten microliters of proteinase
K (20 mg/ml; Qiagen, Manchester, UK) and RNAse-free
water were added (final volume of 900μl). Samples were
incubated at 56°C for 10 min, centrifuged at 10,000 g for
5 min at room temperature and the supernatant trans-
ferred to a fresh tube containing 400 μl 96% ethanol. The
mixture was transferred to RNeasy spin tubes (Qiagen
mini prep), processed according to the manufacturer’s
instructions and eluted in 20 μl RNAse-free water. This
was incubated on the column for at least 5 min at
room temperature before collection. The first eluate was
reapplied to the column and incubated for a further
minute before the final elution.
For sheep hearts, RNA extraction was similar except
that samples were minced prior to lysis for two sessions
each of 3 min.
RNA quantity and integrity were determined using a
Nanodrop (ThermoFisher, UK) spectrophotometer and
gel electrophoresis, respectively.
Reverse transcription and quantitative real-time PCR.
Samples of 500 ng mouse or 300 ng sheep RNA
were reverse transcribed using QuantiTect Reverse
transcription kit (Qiagen, Manchester, UK) and gDNA
wipe-out (to remove genomic DNA), according to the
manufacturer’s protocol. Included in each sample batch
were ‘no template’ and ‘no reverse transcriptase’ controls.
Resultant cDNA samples were stored at -20°C. Primers
and probes used for qPCR are detailed in Table 1.
Assays for mouse qPCR were designed using the Roche
Universal Probe Library and primers were purchased
from Invitrogen (ThermoFisher, UK). A standard curve
prepared from pooled cDNA samples was processed with
samples on a Lightcycler 480 system (Roche Diagnostics,
Burgess Hill, UK). For sheep, Taqman assays (Thermo-
Fisher, UK) were used and performed using a 7900HT
Fast Real Time PCR system (ThermoFisher, UK). Inter-
nal controls were Tbp for mouse, and PGK1 and SDHA
for sheep heart; these did not differ across treatments.
All assays were performed in triplicate. Quantification
was achieved using the PCR machine software, which
calculated 2CT by comparison of unknown sample
values to an external standard curve. Standard curves
passed quality control if they had efficiency within the
range of 1.7–2.1 and error of <0.5). To normalize the
spread, data were log10 transformed. For mouse RNA
data, each data point represents a single litter; either one
fetal heart or the mean of the measurements from two
fetal hearts.
Mitochondrial DNA quantification. DNA was extracted
from frozen samples (n = 6 fetal hearts/genotype) using
a DNeasy Blood and Tissue kit (Qiagen, Manchester, UK)
according to the manufacturer’s protocol. To quantify
mitochondrial DNA relative to nuclear DNA, levels of
mitochondrial-encoded genes (Co1, Co2, Nd2) were
measured relative to an intronless nuclear-encoded
gene (Cebpa) by qPCR, performed in triplicate (primer
sequences in Table 1). At E17.5, cardiomyocytes in mouse
fetal hearts are mono-nucleated (Rog-Zielinska et al.
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
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2013). Moreover, dexamethasone treatment of mouse
fetal cardiomyocytes in vitro has no effect on nucleation
(Rog-Zielinska et al. 2015).
Statistics. Graphpad Prism 8 software was used for
statistical analyses. All data are presented as means
± standard deviation (SD). The number of biological
replicates is provided in the figure legends together with
the statistical tests used for analysis. All data were sub-
ject to Shapiro–Wilk’s normality testing prior to analysis.
Outliers were identified using Grubbs’ test. Two outliers
in total were detected and excluded from the data analysis
(as detailed in the legends to Figs 8 and 9). Parametric
analyses, Student’s t tests and two-way ANOVA with post
hoc Sidak’s tests were used as stated in the figure legends.
Results
Primary fetal cardiomyocytes rely mainly on
mitochondrial oxidation, with little reliance on
glycolysis
The OCR and ECAR were measured in a glycolysis
stress test (without fatty acid). The basal OCR prior
to, and following, addition of 10 mM glucose was
increased by 24 h dexamethasone treatment of primary
fetal cardiomyocytes (Fig. 2A, 2C; P = 0.0247, n = 9
= 10). OCR was markedly decreased following addition
of oligomycin, an inhibitor of ATP synthase (Fig. 2A),
suggesting high dependence of fetal cardiomyocytes on
mitochondrial respiration for ATP production. There
was a modest increase in oligomycin-sensitive OCR
(basal respiration) in fetal cardiomyocytes treated with
dexamethasone, consistent with our previous findings
(Rog-Zielinska et al. 2015) though this did not achieve
significance here (Fig. 2D, P = 0.0729, n = 9 = 10).
The ECAR is a key measure of glycolysis, an important
energy source in early fetal cardiomyocytes (Porter et al.
2011). However, ourmurine primary fetal cardiomyocytes
exhibited little dependence on glycolysis. The addition of
2DG (an inhibitor of glycolysis) had a minimal impact
on ECAR when added either during the glycolysis stress
test (Fig. 2B) or when added to glucose-replete medium
without any other inhibitors (Fig. 2F, 2G;P= 0.765, n= 5)
and was unaffected by dexamethasone treatment (Fig. 2E;
P = 0.103, n = 9 = 10). As expected, addition of the
glycolysis inhibitor 2DG did not alter the OCR (Fig. 2A).
These data suggest primary fetal cardiomyocytes perform
very little glycolysis, relying mainly on mitochondrial
oxidation for ATP production.
Dexamethasone increases palmitate oxidation via GR
activation
To investigate whether dexamethasone can increase
capacity for long-chain fatty acid oxidation in fetal cardio-
myocytes, OCRwasmeasured in the presence of palmitate
in a mitochondrial stress test. Long-chain fatty acids are
linked to carnitine and transported into themitochondrial
matrix by carnitine palmitoyltransferase-1 (CPT-1),
which is inhibited by etomoxir. Following treatment
of primary fetal cardiomyocytes with dexamethasone
for 24 h, in the presence of palmitate there was an
increase in basal OCR (Fig. 3A, 3B; P = 0.00638, n
= 4–5). Furthermore, in the presence of palmitate,
dexamethasone-treated cardiomyocytes showed a
larger change in OCR following oligomycin treatment
(oligomycin-sensitive OCR; Fig. 3C; P = 0.0228, n
= 4–5), indicative of increased mitochondrial ATP
production. Addition of etomoxir attenuated the effect
of dexamethasone on basal OCR and mitochondrial
ATP production (oligomycin-sensitive OCR), so that any
residual effect did not achieve significance (Fig. 3A–3C;
P = 0.108 and P = 0.240, respectively, n = 4–5).
This suggests that dexamethasone increased palmitate
oxidation in fetal cardiomyocytes. Etomoxir itself had
no effect on respiration (P = 0.944), ATP production
(P = 0.608) or maximum respiration capacity (P =
0.961) by fetal cardiomyocytes in the absence of palmitate
(Fig. 1D–1F, n = 5) nor did it affect leak respiration
(Fig. 1G; P = 0.473, n = 5). The dexamethasone-induced
increase in fatty acid oxidation was dependent on
GR, as pre-treatment of the cardiomyocytes with
the GR antagonist, RU486 blocked the increase in
basal respiration and ATP production (Fig. 4A–4C;
P[interaction] = 0.0357 and P = 0.0493, respectively, n =
12).
Dexamethasone upregulates genes involved in
long-chain fatty acid oxidation in fetal
cardiomyocytes
The increase in ability to utilize palmitate as a fuel for
mitochondrial respiration suggests that glucocorticoids
increase mitochondrial capacity for long-chain fatty
acid oxidation. Consistent with the rapid induction
of PGC-1α and other master regulators of lipid
metabolism in dexamethasone-treated fetal cardio-
myocytes (Rog-Zielinska et al. 2015) there was a marked
induction of mRNAs encoding enzymes and transporters
required formitochondrial fatty acid oxidation in primary
fetal cardiomyocytes after treatment with dexamethasone
(Fig. 5). As well as the master transcriptional regulators,
Ppargc1a and Lipin1, 24 h treatment with dexamethasone
induced expression of Lcad (P < 0.0001; n = 4) and
Mcad (P = 0.000308; n = 4) (encoding, respectively,
long-chain acyl dehydrogenase and medium-chain acyl
dehydrogenase), Cd36 (P < 0.0001; n = 4), encoding
cluster of differentiation-36, also known as fatty acid
translocase (a cellular importer of fatty acids), and Cpt1a
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and Cpt1b (P < 0.0001; n = 4), encoding the alpha
and beta subunits, respectively, of CPT-1 (Fig. 5B).
Dexamethasone also increased expression of Ucp2 (P
= 0.00132; n = 4), encoding uncoupling protein 2, an
inner mitochondrial membrane protein that promotes
mitochondrial fatty acid oxidation at the expense of
mitochondrial catabolism of pyruvate (Pecqueur et al.
2008). At just 6 h after addition of dexamethasone,
although Fkbp5, a well-known glucocorticoid target
was strongly upregulated (P < 0.0001; n = 4), levels of
Figure 2. Primary fetal cardiomyocytes rely mainly on mitochondrial oxidation, with little reliance on
glycolysis
Primary fetal cardiomyocytes were prepared by digesting pooled E14.5–15.5 C57BL/6J fetal hearts, then cultured
for 48 h in complete DMEM culture medium. Cardiomyocytes were treated with dexamethasone (Dex, 1 μM)
or vehicle (Veh, 0.01% ethanol). After 24 h, cell culture medium was exchanged for seahorse base medium
(supplemented with 1 mM glutamine) and cardiomyocyte metabolism was analysed by extracellular flux assays.
After three basal measurements, glucose (10 mM) was added, followed by oligomycin (Oligo, 1.5 μM) and
2-deoxyglucose (2DG, 100 mM). Oxygen consumption rate (OCR, A) and extracellular acidification rate (ECAR,
B) were measured three times over 7.5 min following each addition. Measures used to calculate values shown
in panels (C–E) are indicated with brackets in (A) and (B). C, basal OCR was calculated as the mean of the three
basal measurements. D, ATP production was estimated as the maximum change in OCR following the addition of
oligomycin (oligomycin-sensitive OCR). E, glycolysis (2DG-sensitive ECAR) wasmeasured as themaximum change in
ECAR following 2DG treatment. For (F–G), primary fetal cardiomyocytes prepared as above were cultured for 72 h
in complete DMEM culture medium. Complete mediumwas exchanged for seahorse assay medium (supplemented
with 10mMglucose, 1mMGlutaMAX, 1mMpyruvate). F, ECARwasmeasured, after three baselinemeasurements
2DG (100 mM) was added followed by antimycin and rotenone (AR, 2 mM). Three measurements at 2.5 min inter-
vals were recorded after each addition. Measurements were normalized to protein. G, the difference between
ECAR at baseline and after the glycolysis inhibitor, 2DG was used to estimate the level of glycolysis occurring in
these cells. Data are means ± SD and were analysed by Student’s t tests with P< 0.05 as the significance threshold,
P values below this are indicated in bold; n = 9–10 individual wells (C–E) or n = 5 individual wells of primary fetal
cardiomyocytes (G), pooled from 15–30 fetal hearts and analysed at the same time across one experiment.
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Figure 3. Dexamethasone increases fatty acid oxidation
Primary fetal cardiomyocytes, prepared by digesting pooled E14.5–15.5 C57BL/6J fetal hearts, were cultured for
48 h in complete DMEM culture medium then treated with dexamethasone (Dex, 1 μM, red) or vehicle (Veh,
black). After 24 h, medium was exchanged for seahorse assay medium supplemented with 5 mM glucose, 1 mM
pyruvate and 0.5 mM carnitine. Cells were treated with etomoxir (Eto, 6μM) or vehicle (Control) 15 min prior to the
addition of BSA-palmitate (100 μM). After a further 15 min incubation, cardiomyocyte metabolism was analysed
by extracellular flux assay. After three basal measurements, oligomycin was added (Oligo, 1.5 μM) followed by
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 1 μM) then antimycin and rotenone (AR, 2 μM).
Oxygen consumption rate (OCR,A) was measured three times over 7.5 min following each drug addition. Measures
used to calculate values shown in panels (B–E) are indicated with brackets. Non-mitochondrial respiration was
estimated as the mean OCR remaining after AR addition. B, basal respiration was estimated as the mean of the
three basal OCR measurements corrected for non-mitochondrial respiration. C, ATP production was estimated as
the maximum change in OCR following the addition of oligomycin. D, maximum respiration was estimated as the
maximum OCR (following FCCP) corrected for non-mitochondrial respiration. E, leak respiration was estimated as
the mean oligomycin-insensitive OCR corrected for non-mitochondrial respiration. Representative data are from
one experiment performed on cardiomyocytes pooled from 15–30 fetuses across n = 4–5 individual wells of pooled
primary fetal cardiomyocytes. Data are means ± SD and were analysed by two-way ANOVA followed by post hoc
Sidak’s tests with P < 0.05 as the significance threshold, P values below this indicated in bold. Three samples were
excluded due to a technical failure (leakage of AR from the port during basal measurements).
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Nr3c1 mRNA, encoding GR, were downregulated (P
= 0.0017; n = 4; Fig. 5A), though they recovered by
24 h (P = 0.137; n = 4, Fig. 5B). Pre-treatment with
RU486 attenuated the dexamethasone-induced increase
in Ppargc1a, Lcad, Lipin1 and Cd36 mRNAs (P values
for effect of dexamethasone in control vs. RU486-treated
as follows, Ppargc1a - 0.0138 vs. 0.158; Lcad - 0.00600
vs. 0.0186; Lipin1 - 0.0161 vs. 0.115; Cd36 - 0.00232 vs.
0.122; Fig. 6A–6I, n = 4). At E17.5, hearts of GR–/– fetal
mice had reduced levels of Mcad mRNA (P = 0.0365,
n = 5–6). Although the reduction in levels of Ppargc1a
mRNA did not achieve significance (P = 0.210, n = 5–6;
Fig. 6J) we have previously reported reduced Ppargc1a
mRNA in hearts of E17.5 GR–/– fetal mice (Rog-Zielinska
et al. 2013). The failure to reach statistical significance
here likely reflects smaller group sizes and overnight
matings rather than the time-restricted matings adopted
previously.
Glucocorticoids do not cause mitochondrial
remodelling in fetal cardiomyocytes
Because there is a wave of mitophagy in vivo in the mouse
fetal heart that coincides with the peak of fetal cortico-
sterone levels (Rog-Zielinska et al. 2013; McWilliams
et al. 2016), we hypothesized that glucocorticoids
may stimulate the mitophagic replacement of fetal
mitochondria by adult mitochondria optimized for
fatty acid metabolism (Gong et al. 2015). mito-QC trans-
genic mice utilize a binary fluorescence system in which
a ubiquitously expressed tandem mCherry-GFP tag is
directed to mitochondria (McWilliams et al. 2016). Under
steady-state conditions, the mitochondrial network
fluoresces red and green (merged, yellow) in mito-QC
mice. Upon delivery to lysosomes, the GFP fluorescence,
but not that of mCherry, is quenched by the acidic
microenvironment. Thus, mitochondria undergoing
Figure 4. Glucocorticoid receptor (GR) mediates the dexamethasone-induced increase in fatty acid
oxidation
Primary fetal cardiomyocytes, prepared by digesting pooled E14.5–E15.5 C57BL/6J fetal hearts were cultured for
48 h before treatment with RU486 (1 μM) or vehicle (control) 30 min prior to addition of dexamethasone (Dex,
1 μM, red) or vehicle (Veh, black). After 24 h, medium was exchanged for seahorse assay medium supplemented
with 5 mM glucose, 1 mM pyruvate and 0.5 mM carnitine. Cells were treated with etomoxir (Eto, 6 μM) or
vehicle (Control) 15 min prior to addition of BSA-palmitate (100 μM). After 15 min incubation with BSA-palmitate,
cardiomyocytes were subjected to extracellular flux assay. After three basal measurements, oligomycin was added
(Oligo, 1.5 μM) followed by carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 1 μM) and antimycin
and rotenone (AR, 2 μM). Oxygen consumption rate (OCR, A) was measured three times over 7.5 min following
each drug addition. Measures used to calculate values shown in panels (B–E) are indicated with brackets.
Non-mitochondrial respiration was estimated as the average OCR remaining after AR addition. B, basal respiration
was estimated as the mean of the three basal OCR measurements corrected for non-mitochondrial respiration. C,
ATP production was estimated as the maximum change in OCR following addition of oligomycin. D, maximum
respiration was estimated as the maximum OCR measurement corrected for non-mitochondrial respiration. E, leak
respiration was estimated as the average oligomycin-insensitive OCR corrected for non-mitochondrial respiration.
Data are from pooled cardiomyocytes (n = 12 wells of pooled fetal cardiomyocytes across three different pools)
and are means ± SD and analysed by two-way ANOVA followed by post hoc Sidak’s tests with P < 0.05 as the
significance threshold, P values below this indicated in bold.
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mitophagic removal appear as punctate mCherry-only
foci. To investigate whether dexamethasone induces
mitophagy, primary fetal cardiomyocytes from mito-QC
mice were treated with dexamethasone, vehicle or a
mitophagy-inducing agent, DFP (Allen et al. 2013). As
expected,DFP stimulated a robustmitophagy response (as
visualized by an increase in the number of mCherry-only
positive puncta) over the 45 h time course (Fig. 7A). In
contrast, no significant increase in mitophagy could be
seen in cardiomyocytes following a similar time course of
dexamethasone treatment (P = 0.637 at 45 h, n = 17–40;
Fig. 7B). Thus, under these conditions, dexamethasone is
not a potent inducer of mitophagy.
Glucocorticoids have been associated with changes
in mitochondrial number and function (Weber et al.
2002; Du et al. 2009; Lapp et al. 2018). Accordingly,
we next investigated whether the dexamethasone-induced
increase in fatty acid oxidation was associated with
an increase in mitochondrial volume and/or number.
Following dexamethasone treatment of primary fetal
cardiomyocytes for 24 h, mitochondria were labelled
with MitoTracker Deep red CM and the mitochondrial
network imaged (Fig. 7C, 7D). There were no differences
in mitochondrial volume (P = 0.287), length (P =
0.152) or width (P = 0.415) between dexamethasone and
vehicle-treated cardiomyocytes (Fig. 7E–7G, n = 17–40).
Furthermore, mitochondrial DNA content, an indirect
measurement of mitochondrial number, did not differ
between hearts of E17.5 GR–/– mice and their control
GR+/+ littermates (P ≥ 0.355, n = 5–6; Fig. 7H–7J.
Thus, the glucocorticoid-mediated increase in fatty acid
oxidation capacity most likely occurs independently of
any change in mitochondrial number or morphology.
In vivo, dexamethasone-induced changes in fatty acid
oxidation genes in mouse hearts are developmental
stage-dependent
To investigate whether glucocorticoid administration
in vivo can similarly induce cardiac fatty acid oxidation
Figure 5. Dexamethasone increases the expression of genes involved in mitochondrial fatty acid
oxidation
Primary fetal cardiomyocytes, prepared by digesting pooled E14.5–E15.5 C57BL/6J fetal hearts were cultured for
48 h before treatment with dexamethasone (Dex, 1 μM, red) or vehicle (Veh, black) for (A) 6 or (B) 24 h. Cardio-
myocytes were lysed in TRIzol and RNA isolated for analysis by qRT-PCR relative to Tbp, used as internal control.
Data are from n = 4 independent pools of cardiomyocytes, each from 15–30 fetal hearts, prepared on different
days, each data point represents one pool. Data are means ± SD, analysed by paired Fisher’s least significant
difference tests with P < 0.05 as the significance threshold, P values below this indicated in bold.
© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
16 J. R. Ivy and others J Physiol 0.0
capacity, dexamethasone or vehicle was administered
to pregnant dams at E13.5 or E16.5 or to neonatal
mice at postnatal day (P)1. Hearts were examined
24 h after injection. E14.5 fetal hearts appeared
glucocorticoid-resistant: dexamethasone had no
significant effect on any of the mRNAs examined,
including the glucocorticoid target, Fkbp5, and Nr3c1
encoding GR itself (P ≥ 0.0944, n = 5; Fig. 8A). However,
at E17.5, dexamethasone downregulated cardiac Nr3c1
mRNA levels (P = 0.035, n = 5; Fig. 8B). At the same
time, levels of Ppargc1a and mRNA encoding enzymes
and transporters for fatty acid oxidation (Mcad, Lcad,
Lipin1, Cd36, Cpt1a, CPT1b) were strongly down-
regulated (P value range from 0.00234 to 0.0331,
Figure 6. Glucocorticoid receptor (GR) antagonism attenuates the dexamethasone-induced increase in
genes involved in fatty acid oxidation and some of these changes are seen in GR–/– fetal hearts at E17.5
(A–I) primary fetal cardiomyocytes were prepared by digesting 15–30 pooled C57BL6/J fetal hearts at E14.5–15.5.
Cardiomyocytes were cultured for 48 h under standard conditions before being treated with the GR antagonist,
RU486 (1 μM) or vehicle (control, 0.01% ethanol) 30 min prior to treatment with dexamethasone (Dex, 1 μM) or
vehicle (Veh, 0.01% ethanol). After 24 h, the cardiomyocytes were lysed in TRIzol and RNA isolated for analysis by
qRT-PCR. J, GR+/+ and GR–/– hearts were dissected from E17.5 fetuses and RNA extracted for analysis by qRT-PCR.
Data are means ± SD, analysed by repeated measures two-way ANOVA followed by post hoc Sidak’s tests (A–I) or
Fisher’s least significant difference tests with P < 0.05 as the significance threshold, P values below this indicated
in bold. n = 4 independent cardiomyocyte preparations (A–I), n = 5–6 individual fetus hearts, each from a different
litter (J).
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n = 5), despite a significant, albeit modest, increase
in Fkbp5 mRNA (P = 0.0116, n = 5; Fig. 8B). In
complete contrast, at P2, Fkbp5 was strongly induced by
dexamethasone (P < 0.0001, n = 7–8), as was Ppargc1a
(P = 0.0101, n = 7–8) and the fatty acid oxidation genes:
Mcad, Lcad, Cd36, Cpt1b (P = 0.00246, 0.00511, 0.00195
and 0.0416, respectively, n = 7–8; Fig. 8C). Moreover,
levels of Nr3c1 mRNA were unchanged (P= 0.787, n
= 7–8; Fig. 8C). Thus, the effect of glucocorticoids
upon cardiac capacity for fatty acid oxidation reflect the
effect upon GR expression itself and its key target gene,
Ppargc1a. Because this finding was unexpected and has
implications for the use of antenatal corticosteroids in
preterm birth, we extended our investigation to measure
Figure 7. Dexamethasone does not alter mitochondrial morphology or induce mitophagy in primary
fetal cardiomyocytes
Primary cardiomyocytes were isolated from 15–30 pooled E14.5–E15.5 mito-QC (A, B) or C57Bl/6J (C–G) fetal
hearts, then cultured for 48 h. A, B, cardiomyocytes were treated with dexamethasone (Dex, 1 μM), vehicle
(Veh) or a mitophagy-inducing agent, deferiprone (DFP, 1 mM) and imaged live, 3, 8 and 45 h later. z stacks of
individual cells were obtained using a spinning disk confocal microscope (100× magnification). A, representative
maximum z projection images are shown: white arrows indicate examples of puncta in magnified panels. Scale bars
= 10 and 5 μm for main and high magnification panels, respectively. B, puncta were counted manually through z
stacks. Data are means ± SD, n = 17–23 individual cells and analysed by two-way ANOVA with post hoc Sidak’s
tests. C–G, cardiomyocytes were cultured for 48 h then treated with dexamethasone (Dex, 1 μM) or vehicle (Veh)
for 24 h. Mitochondria were labelled with MitoTracker Deep Red CM and cardiomyocyte beating stopped with
nefidipine (100 mM). z stacks of individual cells were obtained using a spinning disk confocal microscope (100×
magnification). Mitochondrial morphology was assessed using MitoGraph software (23, 24) and 3D renderings are
shown for vehicle (C) and dexamethasone (D) treated cardiomyocytes. Parameters included (E) length, (F) width,
and (G) total volume. Data are means ± SD, n = 17–40 individual cells in one representative experiment (each
data point representing one cell) analysed by Student’s t tests. H–J, mitochondrial DNA was quantified by qPCR
of mitochondrially encoded genes: cytochrome c oxidase I (mt-CO1, D), III (mt-CO3, E) and NADH dehydrogenase
II (mt-ND2, F). Absolute values were corrected for genomic Cebpa levels. Data are means ± SD and analysed by
Student’s t tests, n = 6 fetal mouse hearts each from a different litter.
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cardiac mRNA encoding GR and PGC-1α in a trans-
lational sheep model of preterm birth following antenatal
corticosteroid administration that mimics current clinical
practice. Indeed, current clinical practice is based on
experiments conducted on sheep, and the sheep has been
extensively used to investigate the effects of antenatal
glucocorticoids on fetal outcomes including long-term
outcomes, in adulthood (reviewed in Dickinson et al.
2016; Morrison et al. 2018). Although dexamethasone
is used as an antenatal corticosteroid in the UK and
some other countries, celestone, a mix of betamethasone
phosphate and betamethasone acetate, is used clinically
in the USA, Europe, Australia and New Zealand. We have
shown that the slower-release betamethasone acetate, at
the same dose as the betamethasone acetate component
of celestone, shows equivalent efficacy to the clinical drug
in maturing the lungs of fetal rhesus macaques, with the
benefit of reduced corticosteroid exposure (Schmidt et al.
2019b). Accordingly, both celestone and betamethasone
acetate were tested. Preterm lambs delivered at 122 days
(term being ∼147 days) 48 h after initiating a course
of celestone (2 doses, administered 24 h apart) showed
reduced expression of NR3C1 mRNA in both left (P =
0.000903, n = 9 or 11) and right (P = 0.000604, n =
9 or 10) ventricles of the heart (Fig. 9A, 9B). A single
dose of betamethasone acetate (equivalent to just the
betamethasone acetate component of celestone) 24 h
before delivery also reducedNR3C1mRNA levels, though
this did not achieve significance in the right ventricle
(LV and RV, P = 0.00430 and 0.0750, respectively, n =
10 or 11; Fig. 9A, 9B). Levels of PPARGC1 mRNA were
significantly reduced in the right ventricle following
celestone administration (P = 0.00347, n = 9 or 10),
though not in the left ventricle (P = 0.923, n = 9 or 11).
Betamethasone acetate alone caused a non-significant
reduction in PPARGC1 mRNA levels in both ventricles
(LV, P = 0.655; RV, P = 0.203, n = 10–11; Fig. 9C,
9D), consistent with its lower potency compared with
celestone. Thus, in both mice and sheep, antenatal
corticosteroid administration may interfere with the
normal maturation of the mid- to late gestation heart by
downregulating GR.
Discussion
Here, we find that mouse fetal cardiomyocytes in vitro
use mainly oxidative phosphorylation to generate ATP
when glucose is provided as substrate. This supports
the view that metabolism has switched from anaerobic
glycolysis to aerobic mitochondrial respiration by the
Figure 8. Dexamethasone regulates
cardiac mitochondrial fatty acid
oxidation in perinatal mice in vivo
Pregnant C57Bl/6J dams were injected (I.P.)
with 0.5 mg/kg dexamethasone or vehicle
at E13.5 (A) or E16.5 (B). C57Bl/6J neonates
(C) were injected on P1 with
dexamethasone (0.5 mg/kg) or vehicle.
After 24 h hearts were excised and analysed
by qRT-PCR for genes involved in fatty acid
oxidation. For (A, B) n = 5 litters; each data
point represents one litter, with one or two
animals per litter analysed (where two
animals from a litter were analysed, the
mean is shown). One Fkbp5 data point in
the dexamethasone group at E17.5 was
identified as an outlier using Grubbs’ test
and excluded prior to further analysis. For
(C), n = 7–8 neonates with one animal per
litter analysed; each data point represents
one animal. Data are means ± SD and
analysed by unpaired Fisher’s least
significant difference tests, with P < 0.05 as
the significance threshold, P values below
this are indicated in bold.
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end of the embryonic period at E14.5 in mice (reviewed
Porter et al. 2011). Although glucocorticoids increase
basal mitochondrial respiration (confirming previous
findings (Rog-Zielinska et al. 2015)), they have no
effect on glycolysis, ruling out a glucocorticoid-promoted
switch from glycolysis to oxidative metabolism. Our
data do not support a glucocorticoid-mediated increase
in mitochondrial number or change in morphology to
account for the increase in basal respiration. Instead, our
data suggest that glucocorticoid action in the fetal heart
promotes mitochondrial ATP-generating capacity, in line
with the maturational effects of glucocorticoids.
As well as increasing basal mitochondrial respiration
with glucose as substrate, dexamethasone treatment of
fetal cardiomyocytes in vitro increases mitochondrial fatty
acid oxidation. It has been suggested that mitophagy is
required to replace the mitochondrial network in peri-
Figure 9. Cardiac glucocorticoid receptor (GR) and PGC-1α
expression are reduced following treatment with antenatal
corticosteroids in a sheep model of preterm birth
Lambs were delivered preterm at 122 ± 1 days (term being ∼147
days), 48 h after initiating a course of celestone (Cel: 2 doses, 24 h
apart) or 24 h after a single dose of betamethasone acetate (BmA).
A, B, mRNA encoding GR (NR3C1) and (C, D) PGC-1α (PPARGC1A)
were measured by qPCR in the left ventricle (LV) and right ventricle
(RV). Data are means ± SD, data were first analysed with Grubbs’
test and one outlier (in the LV vehicle group) was detected and
removed from the analysis. Subsequently the data were analysed by
ordinary one way ANOVA with post hoc Tukey’s tests with P < 0.05
as the significance threshold, P values below this are indicated in
bold. For RV: Veh n = 10, BmA n = 10, Cel n = 9. For LV: Veh n = 11,
BmA n = 10, Cel n = 9.
natal cardiomyocytes with mitochondria optimized for
fatty acid oxidation (Gong et al. 2015). However, our
data suggest that an increase in fatty acid oxidation
can occur in fetal cardiomyocytes without substantial
mitophagy. Moreover, they are consistent with the notion
that mitochondrial remodelling occurs in cardiomyocytes
prior to our cell isolations at ∼E15. Mitochondrial
phenotype in the embryonic heart changes considerably
between E9.5 and E13.5, compatible with mitochondrial
remodelling by mitophagy being required for the switch
in cardiomyocyte reliance from anaerobic glycolysis to
aerobic respiration. By E13.5, the network is inter-
connected and spans the cell, more closely resembling
that in late fetal cardiomyocytes (Porter et al. 2011).
Our conclusions differ from a recent report that suggests
that dexamethasone promotes mitophagy in mouse
embryonic stem cell-derived cardiomyocytes through
Parkin (Zhou et al. 2020). We note that in those
experiments, detection of lysosomes (using lysotracker)
was only possible in dexamethasone-treated cells (Zhou
et al. 2020) making interpretation of the mitophagy
findings difficult. Nevertheless, dexamethasone did not
affect mitochondrial morphology in mouse embryonic
stem cell-derived cardiomyocytes (Zhou et al. 2020),
consistent with our findings here. Our data reported here
clearly show that although glucocorticoid treatment of
primary mouse fetal cardiomyocytes increases fatty acid
oxidation, it does not induce widespread mitophagy.
Dexamethasone treatment of fetal cardiomyocytes in
vitro increases expression of genes related to fatty acid
oxidation. Fatty acid oxidation genes themselves are
not primary targets of GR in mouse fetal cardio-
myocytes (Rog-Zielinska et al. 2015) and are likely
indirectly regulated by master regulators of fatty acid
oxidation including CEBPβ , PPARα and PGC-1α, which
we have previously shown are primary GR targets in
fetal cardiomyocytes (Rog-Zielinska et al. 2015). The
induction of PPARα by glucocorticoids provides a
plausible mechanism by which dexamethasone increases
genes in the mitochondrial fatty acid oxidation pathway:
PPARα target genes include those responsible for almost
every step of mitochondrial fatty acid oxidation as well
as fatty acid import into mitochondria (Rakhshandehroo
et al. 2010). Other mechanisms may contribute to
the increase in fatty acid oxidation resulting from
dexamethasone treatment of fetal cardiomyocytes in
vitro. We have previously shown Atp5g2, encoding a
subunit of the F0 component (the proton channel) of
mitochondrial ATP synthase to be a direct target of
GR and rapidly induced by dexamethasone in fetal
cardiomyocytes (Rog-Zielinska et al. 2015). This suggests
that glucocorticoids have the potential to directly alter
the capacity for ATP generation through oxidative
phosphorylation. Complexes I to IV are not direct targets
of GR, so if their expression is altered by dexamethasone,
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this is likely indirect. CPT-1 is not a direct target of
GR in fetal cardiomyocytes (Rog-Zielinska et al. 2015).
However, CD36, a cell surface receptor also known
as fatty acid translocase is a direct target of GR and
is increased in the current study. This is likely to
increase capacity of cardiomyocytes to import fatty acids,
available for their mitochondrial oxidation. In sum, our
data in vitro provide proof-of-principle evidence that
glucocorticoids can increase capacity for mitochondrial
fatty acid oxidation in fetal heart maturation.
Fatty acid oxidation dramatically increases around the
end of the first postnatal week in mouse heart (Lopaschuk
& Jaswal, 2010). However, in preparation for postnatal
life, fatty acid oxidation has already begun to occur in
the late gestation fetal heart (Lopaschuk & Jaswal, 2010;
Porter et al. 2011). In sheep, there is an increase in
cardiac expression of genes related to fatty acid oxidation
between late gestation and term that continues after
birth (Richards et al. 2015). In silico transcription factor
analysis suggests that this is, at least in part, GR-mediated
(Richards et al. 2015). The lower level of Mcad mRNA in
hearts of GR knockout fetuses at E17.5, a stage when end-
ogenous glucocorticoid levels have increased, supports a
role for GR in the normal late gestation increase in cardiac
expression of genes required for fatty acid oxidation. Thus,
endogenous glucocorticoid action, via GR, may contribute
to the normal rise in fatty acid oxidation capability as the
fetus approaches term. This is likely to be important to
meet the increase in cardiac energy demand after birth,
consistent with the ergogenic effects of glucocorticoids
(Addison, 1855; Morrison-Nozik et al. 2015) and the vital
role of the late gestation increase in glucocorticoids to pre-
pare for life after birth.
Crucially, our data illustrate how exogenous
glucocorticoid may interfere with the normal maturation
of energy metabolism in the late gestation fetal heart –
and potentially other aspects of normal cardiomyocyte
maturation –bydownregulating the capacity to respond to
glucocorticoids. Although dexamethasone administration
in vivo in neonatesmarkedly induces cardiac expression of
genes involved in the fatty acid oxidation pathway, similar
to fetal cardiomyocytes in vitro, dexamethasone has the
opposite effect in the late gestation mouse fetal heart.
This striking difference between the in vitro response
of fetal cardiomyocytes and the in vivo response in the
late gestation heart plausibly reflects different responses
of GR itself to treatment. In the E17.5 fetal heart, the
reduction in Nr3c1 mRNA following dexamethasone
treatment suggests the decrease in the mitochondrial
fatty acid oxidation pathway reflects downregulation of
glucocorticoid signalling per se. We recently reported
similar downregulation of GR expression in fetal heart
as well as reduced endogenous fetal corticosterone levels
following dexamethasone treatment (via drinking water)
between E12.5 and E15.5 (Agnew et al. 2019). This
was associated with a transient alteration in fetal diastolic
heart function (Agnew et al. 2019).Whilst dexamethasone
also downregulates Nr3c1mRNA in fetal cardiomyocytes
in vitro, this is transient with recovery of Nr3c1 mRNA
expression by 24 h. In the neonatal heart, if Nr3c1
mRNA is transiently downregulated by dexamethasone,
it has recovered within 24 h. Dynamic and differential
autoregulation of GR, previously described for adult
tissues (Kalinyak et al. 1987; Spencer et al. 1991;
Freeman et al. 2004), may contribute to the complex
and context-dependent effects of perinatal glucocorticoid
administration. Previous studies have examined the effect
of antenatal glucocorticoids in rodents and reported
contradictory findings (reviewed, Rog-Zielinska et al.
2014). Although this likely involves differences in the
nature of the administered glucocorticoid, for example,
cortisol or corticosterone vs. dexamethasone, our findings
support dependence on the timing as well. Importantly,
they illustrate that during particular gestational windows,
exogenous glucocorticoids may interfere with normal
heart maturation. Indeed, maturation of the rat heart
is delayed after prenatal treatment with dexamethasone
(Torres et al. 1997). GR expression was not examined in
that study. Investigations in sheep have also highlighted
adverse effects of antenatal glucocorticoid exposure on
cardiac energy metabolism. Maternal hypercortisolaemia
reduces fetal cardiac mitochondrial number and
oxidative metabolism at term, associated with fetal
ECG abnormalities, an inability to maintain fetal aortic
pressure and heart rate during labour and a dramatic
increase in perinatal death (Antolic et al. 2018). Again,
whether GR expression was affected was not reported.
In our experiments, cardiac expression of GR in preterm
neonates was reduced following exogenous glucocorticoid
administration in late gestation in sheep, similar to the
downregulation that occurred in fetal mice. This likely
limits the capacity to respond to glucocorticoids in sheep
heart. Despite considerable differences in the physio-
logy of gestation between mice and sheep (Dickinson
et al. 2016) and given that the lambs were born (albeit
for less than 40 min) whereas the mice were fetuses,
this suggests downregulation of GR may be a common
response to antenatal corticosteroids. Downregulation
of GR and ability to respond to glucocorticoids may
be a mechanism that contributes to the well-known
association between early-life exposure to synthetic
glucocorticoids and chronic adult cardiovascular disease
(Fowden et al. 1998; Rog-Zielinska et al. 2014). Whilst
effects on hypothalamic-pituitary-adrenal axis activity
and blood pressure may play a role in the programming
of cardiovascular disease risk, our data support direct
effects on cardiomyocytes as well. Recent evidence
suggesting that prenatal dexamethasone exposure alters
the trajectory of perinatal heart maturation through
alterations in cardiomyocyte mitochondrial function is
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also consistent with direct actions in heart (Peng et al.
2018).
Differential mRNA stability may explain some of the
complex effects of glucocorticoids on downstream genes.
PGC-1α is essential for efficient and maximal fatty acid
oxidation and ATP production in cardiomyocytes (Arany
et al. 2005; Lehman et al. 2008). Ppargc1a mRNA has a
short half-life, being less than 30min in rat skeletal muscle
extracts. This is further decreased with chronic muscle
stimulation (Lai et al. 2010). Consistent with a short
half-life, we have previously shown that blocking new
protein synthesis with cycloheximide increases Ppargc1a
mRNA levels in fetal cardiomyocytes (Rog-Zielinska et al.
2015), suggesting it is actively degraded. Glucocorticoid
treatment rapidly increases levels of Ppargc1a mRNA in
fetal heart in vivo and in fetal cardiomyocytes in vitro
(Rog-Zielinska et al. 2015). Moreover, dexamethasone
‘super-induces’ Ppargc1a in the presence of cycloheximide
(Rog-Zielinska et al. 2015), again consistent with a rapid
turnover of Ppargc1a mRNA. A very short half-life
and a need for activated GR to continually enhance
transcription of Ppargc1a mRNA may explain the close
association between Nr3c1 and Ppargc1a mRNA in both
fetal heart andmouse primary cardiomyocytes thatwe saw
here. By contrast, in vitro in fetal cardiomyocytes, Fkbp5
mRNAwas upregulated by dexamethasone, despite trans-
ient down-regulation of GR at 6 h. Fkbp5 mRNA may be
a stable readout of early GR activation whereas Ppargc1a
mRNA correlates with Nr3c1 mRNA at any particular
time. Plausibly, antentatal corticosteroids may disrupt the
normal maturation of energy metabolism in the human
fetal heart, in part by downregulating PGC-1α. In our
sheep model, which closely mirrors clinical practice, both
Nr3c1 and Ppargc1a were downregulated in fetal heart
by antenatal corticosteroids. Whether this is transient,
and both later recover to control levels merits further
investigation. Nevertheless, this suggests that clinical
administration of antenatal corticosteroids in mid- and
late gestationmay interfere with normal heart maturation.
The E13.5 fetal heart appears resistant to
dexamethasone. The reason for this is unclear, but
it has implications for clinical practice. In humans,
the reduction in fetal heart rate variability (a clinical
marker of fetal hypoxia/poor outcomes) 2 to 3 days after
maternal administration of glucocorticoids is greater
in fetuses of >30 weeks gestation than those at <30
weeks (Mulder et al. 2009), consistent with gestation
stage-dependent effects of antenatal glucocorticoids.
The greater sensitivity to the haemodynamic effects
of glucocorticoids coincides with an increase in fetal
cortisol synthesis, from ∼30 weeks gestation (Hillman
et al. 2012). In mice, adrenal steroidogenesis initiates
at E14.5 (Michelsohn & Anderson, 1992). This raises
the possibility that the fetus is glucocorticoid-resistant
prior to the gestational increase in fetal glucocorticoid
levels. Conceivably, this might reflect mistiming relative
to the ontogeny of thyroid hormone production discussed
above. It is intriguing to speculate that glucocorticoids
may act in concert with thyroid hormones to increase
cardiac mitochondrial oxidative capacity in preparation
for birth. In skeletal muscle of fetal sheep, mitochondrial
oxidative capacity positively correlates with plasma
thyroid hormone (T3 and T4) and cortisol levels (Davies
et al. 2020). The increase in thyroid hormones under-
lies the gestational increase in mitochondrial density
in ovine fetal skeletal muscle, whereas it has no effect
on expression of PGC-1α (Davies et al. 2020). We have
previously shown that the Dio2 gene encoding the
enzyme responsible for converting T4 to active T3, is
a glucocorticoid target gene in fetal cardiomyocytes
(Rog-Zielinska et al. 2015). This supports the inter-
dependence of glucocorticoid and thyroid hormone
actions in maturation of fetal organs and tissues and
raises the possibility that mistimed elevations in plasma
glucocorticoid levels might occur at inappropriate (for
stage) thyroid hormone levels potentially manifesting
as glucocorticoid resistance. A permissive role for T3
for dexamethasone to mediate effects on the electro-
physiology of human pluripotent stem cell-derived
cardiomyocytes has been described (Birket et al. 2015).
Whether the fetus is glucocorticoid-resistant prior
to initiation of adrenal steroidogenesis merits future
investigation, given widespread expression of GR in the
mouse fetus prior to E14.5 (Rog-Zielinska et al. 2013).
It is interesting to note that although dexamethasone
increases calcium handling and contraction force in
human embryonic stem cell-derived cardiomyocytes
(Kosmidis et al. 2015), human induced pluripotent stem
cell-derived cardiomyocytes (roughly corresponding to
first trimester human fetal cardiomyocytes (van den Berg
et al. 2015)) do not respond to dexamethasone alone
(requiring T3), possibly because they lack a competence
factor (Birket et al. 2015). The acquisition of competence
to respond to glucocorticoids as well as the autoregulation
of GR itself may therefore be developmentally regulated
andmay differ between cell types. Understanding how this
contributes to the maturational effects of glucocorticoids
upon fetal organs and tissues will be vital to optimize
antenatal corticosteroid therapy in the future, to limit
possible harm and maximize benefit.
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